Survey of Ophthalmology
Volume 47 , Pages S97-S104 , August 2002

Current Status of Prostaglandin Therapy: Latanoprost and Unoprostone

  • Remo Susanna Jr, MD

      Affiliations

    • Corresponding Author InformationReprint address: Remo Susanna, Jr, MD, Associate Professor University of São Paulo, Glaucoma Service Director, Department of Ophthalmology, 05455-000 Av. São Gualter 99, São Paulo, Brazil
    • University of São Paulo, Department of Ophthalmology, São Paulo, Brazil
    • ,
  • Paul Chew, FRCSE

      Affiliations

    • National University of Singapore, Department of Ophthalmology, Singapore, Singapore
    • ,
  • Yoshiaki Kitazawa, MD

      Affiliations

    • Gifu University, Akasaka Kitazawa Eye Clinic, Tokyo, Japan

References 

  1. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  2. Alm A, Widengard I. Latanoprost (experience of 2-year treatment in Scandinavia). Acta Ophthalmol Scand. 2000;78:71–76
  3. Alm A, Widengard I, Kjellgren D, et al.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12–16
  4. Altuna JC, Greenfield DS, Wand M, et al.  Latanoprost in glaucoma associated with Sturge–Weber syndrome (benefits and side-effects). J Glaucoma. 1999;8:199–203
  5. Aung T, Chew PT, Yip CC, et al.  A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 2001;131:636–642
  6. Aung T, Wong HT, Yip CC, et al.  Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma (a preliminary study). Ophthalmology. 2000;107:1178–1183
  7. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol. 1998;116:679–680
  8. Ayyala RS, Cruz DA, Margo CE, et al.  Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol. 1998;126:602–604
  9. Azuma I, Masuda K, Kitazawa Y, et al.  Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol. 1993;37:514–525
  10. Azuma I, Masuda K, Kitazawa Y, et al.  Phase II double-masked dose-determination study of UF-021 ophthalmic solution in primary open-angle glaucoma and ocular hypertension. Folia Ophthalmol Jpn. 1992;43:1425–1431
  11. Blumbaker RF. Importance of outflow facility. Int Glaucoma Rev. 2001;3:10
  12. Bucci MG. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol (a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group). J Glaucoma. 1999;8:24–30
  13. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol. 1998;126:134–135
  14. Camras CB. Latanoprost may trigger the biosynthesis of endogenous prostaglandins in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:1265–1266
  15. Camras CB, Neely DG, Weiss EL. Latanoprost-induced iris color darkening (a case report with long-term follow-up). J Glaucoma. 2000;9:95–98
  16. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma (a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group). Ophthalmology. 1996;103:138–147
  17. Camras CB, Wax MB, Ritch R, et al.  Latanoprost treatment for glaucoma (effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group). Am J Ophthalmol. 1998;126:390–399
  18. Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987;105:1112–1116
  19. DesMarchais B, Candal E, Weitzman M, Shields MB. Effect of latanoprost as adjunctive therapy. Can J Ophthalmol. 2000;35:214–217
  20. Diestelhorst M. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. A 6-month, randomized, multicenter study. German Latanoprost Study Group. Graefes Arch Clin Exp Ophthalmol. 2000;238:433–439
  21. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70:563–569
  22. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 2000;238:19–23
  23. Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS. 1999;3:33–39
  24. Frankelson EN. The role of the water test in evaluation of glaucoma control. Can J Ophthalmol. 1974;9:408–410
  25. Fristrom B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662–665
  26. Fujimori C, Yamabayashi S, Hosoda M, et al: [The clinical evaluation of UF-021, a new prostaglandin related compound, in low tension glaucoma patients]. Nippon Ganka Gakkai Zasshi 97:1231–5, 1993
  27. Gaddie IB, Bennett DW. Cystoid macular edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69:122–128
  28. Greve EL, Rulo AH, Drance SM, et al.  Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma (a review of short-term studies with three dose regimens of latanoprost treatment). Surv Ophthalmol. 1997;41(Suppl):S89–S92
  29. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol. 1999;117:394–396
  30. Hariton C, Marce D, Debon C. Transitory models of experimentally induced intraocular pressure changes in the rabbit. A reappraisal. J Pharmacol Methods. 1990;24:79–88
  31. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95–104
  32. Heier JS, Steinert RF, Frederick AR. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol. 1998;116:680–682
  33. Helal-Jr J. Contribuição ao estudo da pressão intra-ocular (picos de pressão intra-ocular na curva diária de pressão e na prova de sobrecarga hı́drica). Rev Bras Oftalmol. 1988;47:75–80
  34. Hung PT, Hsieh JW, Chen YF, Wei T. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J Ocul Pharmacol Ther. 2000;16:43–47
  35. Iwakuchi Y, Tanahashi T, Shirao Y. Iris pigmentation in two cases following topical instillation of isopropyl unoprostone. Jpn J Clin Ophthalmol. 1999;53:971–974
  36. Japan Xalatan Study Group: A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula), unpublished.
  37. Johnstone MA. Brief latanoprost rx induces hypertrichosis. Invest Ophthalmol Vis Sci. 1998;39(Suppl):S258; [abstract]
  38. Kashiwaki K, Jim M, Susuki M, et al.  Isopropyl unoprostone increases the activity of matrix metalloproteinases in cultured monkey ciliary muscle cells. J. Glaucoma. 2001;10:271–276
  39. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999;127:531–536
  40. Kent AR, Vroman DT, Thomas TJ, et al.  Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension. J Glaucoma. 1999;8:257–262
  41. Kimura T, Ono J, Ishii R, et al.  Additive hypotensive effect of isopropyl unoprostone ophthalmic solution. Jpn J Clin Ophthalmol. 1999;53:1869–1876
  42. Konstas AG, Maltezos AC, Gandi S, et al.  Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999;128:15–20
  43. Lima MC, Paranhos A, Salim S, et al.  Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost. J Glaucoma. 2000;9:317–321
  44. Lindsey JD, Kashiwagi K, Kashiwagi F. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism (implications for uveoscleral outflow). Surv Ophthalmol. 1997;41(Suppl):S53
  45. Lindsey JD, Kashiwagi K, Kashiwagi F. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214–2297
  46. Manni G, Bucci M, the Italian Association for the Study of Glaucoma . Substitution with latanoprost monotherapy or additional with dorzolamide in timolol treated patients. A randomized, multicenter study in Italy. Invest Ophthalmol Vis Sci. 2000;41(Suppl):S281; [abstract]
  47. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 2000;118:718–719
  48. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology. 1999;106:550–555
  49. McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye. 1999;13:31–34
  50. Miller D. The relationship between diurnal tension variation and the water-drinking test. Am J Ophthalmol. 1964;58:243–247
  51. Mishima HK, Kiuchi Y, Takamatsu M, et al.  Circadian intraocular pressure management with latanoprost (diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow). Surv Ophthalmol. 1997;41(Suppl 2):S139–S144
  52. Mishima HK, Masuda K, Kitazawa Y, et al.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol. 1996;114:929–932
  53. Miyake K, Ota I, Maekubo K, et al.  Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34–40
  54. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al.  Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology. 1999;106:1024–1029
  55. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716
  56. Nordmann JP, Rouland JF, Mertz BP. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension. Curr Med Res Opin. 1999;15:87–93
  57. Nordmann JP, Soderstrom M, Rouland JF, Malecaze F. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Group. Br J Ophthalmol. 2000;84:181–185
  58. O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension (a 3 month, randomised study). Ireland Latanoprost Study Group. Br J Ophthalmol. 2000;84:579–582
  59. Orzalesi N, Rossetti L, Invernizzi T, et al.  Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–2573
  60. Patelska B, Greenfield DS, Liebmann JM, et al.  Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 1997;124:279–286
  61. Pfeiffer N, the German Latanoprost Fixed Combination Study . A comparison of the fixed combination of latanoprost and timolol with its individual components in patents with glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41(Suppl):S754; [abstract]
  62. Pfeiffer N, Grierson I, Goldsmith H, et al.  Histological effects in the iris after 3 months of latanoprost therapy (the Mainz 1 study). Arch Ophthalmol. 2001;119:191–196
  63. Pfeiffer N, Yannoulis N, Mertz B, et al.  Efficacy and safety of unoprostone 0.15% and latanoprost 0.005% in adjunctive therapy to timolol maleate 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(Suppl):S820; [abstract]
  64. Prota G, Vincensi MR, Napolitano A, et al.  Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 2000;13:147–150
  65. Racz P, Ruzsonyi MR, Nagy ZT, et al.  Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114:268–273
  66. Reis A, Althaus C, Sundmacher R: [Latanoprost (Xalatan)-induced macular edema]. Klin Monatsbl Augenheilkd 213:63–4, 1998
  67. Rowe JA, Hattenhauer MG, Herman DC. Adverse side effects associated with latanoprost. Am J Ophthalmol. 1997;124:683–685
  68. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103:1276–1282
  69. Rulo AH, Greve EL, Hoyng PF. Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899–902
  70. Schachtschabel U, Lindsey JD, Weinreb RN. The mechanism of action of prostaglandins on uveoscleral outflow. Curr Opin Ophthalmol. 2000;11:112–115
  71. Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid-induced glaucoma. J Glaucoma. 2000;9:179–182
  72. Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema (is there a causal relation?). Curr Opin Ophthalmol. 2000;11:94–100
  73. Semba A, Toyonaga M, Nishioka Y, et al.  Hypertrichosis caused by topical unoprostone. Jpn J Clin Ophthalmol. 2000;54:775–778
  74. Serle JB, Podos SM, Kitazawa Y, Wang RF. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol. 1998;42:95–100
  75. Shin DH, McCracken MS, Bendel RE, et al.  The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology. 1999;106:386–390
  76. Smith SL, Pruitt CA, Sine CS, et al.  Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668–672
  77. Stewart WC, Sharpe ED, Day DG, et al.  Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000;16:251–259
  78. Stewart WC, Sharpe ED, Stewart JA, et al.  Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%. Am J Ophthalmol. 2001;131:339–344
  79. Stewart WC, Stewart JA, Kapik BM. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure. J Glaucoma. 1998;7:388–394
  80. Susanna R. Incidência de edema cistóide de mácula com o uso de Xalatan(em afácicos e pseudofácicos. Rev Bras Oftalmol. 1998;57:267–269
  81. Susanna R, Giampani J, Borges AS, et al.  A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108:259–263
  82. Susanna R, Nicolela MT, Oga E. Additive effect of latanoprost to the combination of timolol and dorzolamide. J Glaucoma. 2000;9:183–186
  83. Suzuki M, Mishima HK, Masuda K, et al.  Efficacy and safety of latanoprost eye drops for glaucoma treatment (a 1-year study in Japan). Jpn J Ophthalmol. 2000;44:33–38
  84. Takase M, Namba H, Kato M, et al.  Early phase II study of UF-021 ophthalmic solution in primary open-angle glaucoma or ocular hypertension patients. J Eye. 1992;9:1917–1925
  85. Tamada Y, Taniguchi T, Murase H, et al.  Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2001;17:19–25
  86. Taniguchi T, Kitazawa Y. Future developments. In:  Alm A,  Kanfman PL,  Kitazawa Y, et al. editor. Uveoscleral Outflow Biology and Clinical Aspects. St Louis: Mosby-Wolf; 1998; p 90
  87. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use. Ophthalmology. 1998;105:1981–1983
  88. Tsukamoto H, Yokoyama T, Okada K, et al.  Substituting latanoprost (Xalatan) for isopropyl unoprostone (Rescula) in monotherapy and combination therapy. Acta Ophthalmol Scand. 2000;78:604–605
  89. Varnell ED, Toshida H, Kaufman HE, Thompson HW. Differences in topical latanoprost and unoprostone on acute and recurrent herpetic keratitis in the rabbit. Invest Ophthalmol Vis Sci. 2000;41(Suppl):S57; [abstract]
  90. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127:602–604
  91. Wardrop DR, Wishart PK. Latanoprost and cystoid macular oedema in a pseudophake. Br J Ophthalmol. 1998;82:843–844
  92. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263–268
  93. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  94. Watson PG. Latanoprost. Two years experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82–87
  95. Weinreb RN, Kashiwagi K, Kashiwagi F, et al.  Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38:2772–2780
  96. Wistrand P, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl):S129–S138
  97. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 1997;6:430–432
  98. Yang CB, Freedman SF, Myers JS, et al.  Use of latanoprost in the treatment of glaucoma associated with Sturge–Weber syndrome. Am J Ophthalmol. 1998;126:600–602
  99. Yoshikawa K, Inoue T, Inoue Y. Normal tension glaucoma (the value of predictive tests). Acta Ophthalmol (Copenh). 1993;71:463–470

☆ The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(02)00308-9

Survey of Ophthalmology
Volume 47 , Pages S97-S104 , August 2002

Article Tools

* Image Usage & Resolution